• Caprotec Bioanalytics GmbH, of Berlin, received €6 million (US$8.8 million) in two rounds of financing from Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds and private investors for further development and marketing of the company's CCMS platform technology for analyzing complex protein mixtures. Caprotec's CCMS (Capture Mass Spectrometry) technology is designed to isolate proteins directly and selectively from a complex cellular environment, and also can be applied both in water-soluble and membrane protein mixtures, for investigating the interactions of small molecules with the proteome.

• Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., secured a commitment for $15 million in equity financing from institutional investors to support general corporate purposes. The company is placing common stock to investors at a 3 percent discount to the market price. Nymox, which develops drugs and diagnostic products, most recently completed two-year follow-up data from a Phase II study of NX-1207 in benign prostatic hyperplasia and has several other programs in development targeting E. coli infection, Alzheimer's disease, oncology and infectious disease. Shares of Nymox (NASDAQ:NYMX) closed at $5.25 Monday, with no change.